Cystic Fibrosis News and Research RSS Feed - Cystic Fibrosis News and Research

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus.

Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

In the airways, this mucus causes a persistent cough, wheezing, breathlessness, and repeated lung infections. In the digestive tract, the tubes that carry digestive enzymes from the pancreas into the small intestine become blocked, preventing the proper absorption of food nutrients. This can lead to poor weight gain, intestinal blockage (particularly in newborns), and foul-smelling, greasy stools.

There is no cure for cystic fibrosis, so treatment aims to ease symptoms and make the condition easier to live with. Bronchodilators may be used to help expand the airways, antibiotics to treat chest infections and physiotherapy can help expel mucus from the lungs.
The condition is most common in white people of northern European descent and is estimated to occurs in 1 in every 2,500 babies born in the UK, where babies are screened at birth for cystic fibrosis as part of the National Health Service newborn screening programme.
Key finding may point to immediate cause of CF exacerbations

Key finding may point to immediate cause of CF exacerbations

In the genetic disorder cystic fibrosis (CF), the most severe symptoms are recurring episodes of lung inflammation and bacterial infection (known as "exacerbations") that happen from one to three times a year and cause ever-increasing amounts of lung damage through the course of a CF patient's life. [More]
Publicly insured Americans who undergo lung transplantation fare worse than their UK counterparts

Publicly insured Americans who undergo lung transplantation fare worse than their UK counterparts

Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation's government-funded National Health Service. [More]
Male genetic diversity declined due to wealth, power rather than `survival of fittest`

Male genetic diversity declined due to wealth, power rather than `survival of fittest`

The DNA you inherit from your parents contributes to the physical make-up of your body -- whether you have blue eyes or brown, black hair or red, or are male or female. [More]
Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease. [More]
Survey: Number of UK adults living with cystic fibrosis expected to increase by 2025

Survey: Number of UK adults living with cystic fibrosis expected to increase by 2025

The number of people living with cystic fibrosis into adulthood in the UK is expected to increase dramatically - by as much as 80 per cent - by 2025, according to a Europe-wide survey, the UK end of which was led by Queen's University Belfast. [More]
New bodily process may explain low blood oxygen levels for cystic fibrosis patients with lung infection

New bodily process may explain low blood oxygen levels for cystic fibrosis patients with lung infection

Researchers have defined a new bodily process in mice that may explain why blood oxygen levels are lower for patients with cystic fibrosis when they get a lung infection. [More]
New research lays groundwork for developing treatments for asthma, COPD

New research lays groundwork for developing treatments for asthma, COPD

In diseases such as asthma and chronic obstructive pulmonary disease (COPD), the body produces too much mucus, making breathing difficult. New research from Washington University School of Medicine in St. Louis provides clues to potentially counteract inappropriate mucus production. [More]
New method of testing deadly pathogen could help combat cystic fibrosis

New method of testing deadly pathogen could help combat cystic fibrosis

A new method of testing the most common cause of life-threatening infection in people with cystic fibrosis could improve efforts to study and combat the illness. [More]
Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement. [More]
Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Treating respiratory disease is often difficult because drugs have to cross biological barriers such as respiratory tissue and mucosa, and must therefore be given in large quantities in order for an effective amount to reach the target. [More]

Preventing lung infections in childhood could help people with cystic fibrosis during adulthood

Preventing lung infections in childhood could stop later life-threatening infections for people with cystic fibrosis (CF), according to the latest research carried out at Aston University. [More]
Finding may help advance experimental approach to improving public health

Finding may help advance experimental approach to improving public health

Scientists have discovered a new way to manipulate how cells function, a finding that might help advance an experimental approach to improving public health: DNA vaccines, which could be more efficient, less expensive and easier to store than traditional vaccines. [More]
UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

Margaret Riley, an evolutionary biologist at the University of Massachusetts Amherst and pioneer in fighting antibiotic-resistant bacteria, announced this week that she is partnering with a Chinese scientist to develop a new drug platform, pheromonicins. The Chinese government is committing $400 million per year to support the newly created Pheromonicin Institute of Beijing. [More]

Garlic compound can help fight lung infections in people with cystic fibrosis

A chemical found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests. [More]
N30 Pharmaceuticals becomes Nivalis Therapeutics

N30 Pharmaceuticals becomes Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR). [More]
Finding opens avenues of research toward precision treatments to boost life expectancy for CF patients

Finding opens avenues of research toward precision treatments to boost life expectancy for CF patients

Mutation of one gene is all it takes to get cystic fibrosis (CF), but disease severity depends on many other genes and proteins. For the first time, researchers at the UNC School of Medicine have identified genetic pathways - or clusters of genes - that play major roles in why one person with CF might never experience the worse kinds of symptoms while another person will battle severe airway infection for a lifetime. [More]
Possible cause of liver disease identified in adolescents with cystic fibrosis

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis. [More]
World class drug discovery team launches new company to tackle chronic respiratory disease

World class drug discovery team launches new company to tackle chronic respiratory disease

Respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma represent a major unmet medical need and a significant health burden in both the developed and developing world. [More]
Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals, Inc. today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA. [More]
Advertisement
Advertisement